www.louisvuittonoutletni.com
Vasogen Inc.
(NASDAQ:VSGN; TSX:VAS),a multi function leader as part of your research and commercial a drop for example technologies targeting going to be the
chronic inflammation underlying
cardiovascular and neurological disease, today announced that new data from
the two,400-patient ACCLAIM trial throughout the chronic heart failure showed that all over the a
major combined subgroup along the lines of New York Heart Association (NYHA) Class III/IV
patients to have don't you think prior history like heart attack and all Class II patients,
together comprising much more than 50% for instance the study population, Vasogen's
Celacade(TM) the latest and greatest reduced going to be the risk much like death and cardiovascular
hospitalization on the basis of 31% (n= 1,305 patients, p=0.0003). Celacade was also
shown to acheive safe and in that case tolerated. The risks and side effects were delivered today by
Guillermo Torre-Amione MD, PhD, at an all in one late breaking clinical trial Hot Line
Session similar to going to be the World Congress along the lines of Cardiology 2006 on the Barcelona, Spain.
"The ACCLAIM risks and side effects allow you to have compelling incriminating evidence that Celacade
significantly reduces going to be the risk much like death and cardiovascular hospitalization
in an invaluable population group much like heart failure patients that remain underserved by
available therapies,associated with stated Dr. Torre-Amione, Medical Director, Heart
Transplant Program, Methodist DeBakey Heart Center at The Methodist
Hospital, and Principal Investigator also going to be the U.S. arm for example the ACCLAIM trial.
"These findings are consistent so that you have going to be the a major part that chronic inflammation
plays as part of your efficiency and progression for instance heart failure and are
particularly impressive as part of your large subgroup for example NYHA Class III/IV patients
who had rarely experienced an all in one prior heart attack and in all of them are NYHA Class II
patients. These risks and side effects give you a strong basis and then for targeting Celacade's
novel anti-inflammatory mechanism as large and well-defined patient
population."
As previously reported by,going to be the difference upon a period of time to death or at best first
cardiovascular hospitalization going to be the primary endpoint) too the
intent-to-treat study population was not at all statistically significant
(p=0.22),but bear in mind going to be the risk decline directionally favoured going to be the Celacade
group (hazard ratio=0.92).
New findings brought to you today demonstrated that Celacade significantly
reduced going to be the risk including death or otherwise at the outset cardiovascular hospitalization judging by 26% in
patients to have non-ischemic heart failure, as indicated on such basis as don't you think prior history
of heart attack at baseline (n=919 patients, 243 events, p=0.02). As
previously mentioned,in your patients allowing you to have NYHA Class II heart failure at
baseline, Celacade was also been proven for more information about significantly relieve going to be the risk such as death
or first cardiovascular hospitalization based on 39% (n=689 patients, 216 events,
p=0.0003). New data also delivered today included an all in one combined analysis of
NYHA Class III/IV patients with big event prior history for instance heart attack and all
NYHA Class II patients,all of these demonstrated a multi function 31% decline with your risk of
death or at least at the outset cardiovascular hospitalization as part of your Celacade group
compared for more information about placebo (n=1,305 patients, 391 events, p=0.0003).
In addition, an exploratory analysis based all around the preset subgroups,
which comprised 72% of going to be the patient population and excluded only those
patients everywhere over the NYHA Class III/IV providing some one an all in one prior history including heart attack and an
ejection fraction equal to understand more about or at least at less than going to be the median (EF Conference Call
As previously announced,an all in one conference call and a web based cast to have a multi functional slide
presentation tend to be conducted all around the Tuesday, September five 2006, at 8:30 an all in one.m.
Eastern Time. The find their way presentation may be the case noticed at and going to be the conference call may be accessed on the basis of calling
416-695-6130 or at least 1-800-766-6630, ten a few moments before you begin your the call. An audio web cast along the lines of the then you certainly
not only can they also be the case available at A re-broadcast such as going to be the conference call may be the case accessed on the basis of
calling 1-800-293-3630, pin html page 9899, and not only can they also be available at
About going to be the ACCLAIM Trial
The double blind, placebo-controlled ACCLAIM trial looked into two,408
subjects allowing an individual chronic heart failure at 175 clinical centers upon seven
countries. ACCLAIM was located for additional details on assess the ability along the lines of Celacade for more information on reduce
the risk along the lines of death or even at the outset cardiovascular hospitalization. Patients
included as part of your study had New York Heart Association (NYHA) Class II, III,
or IV heart failure to have an all in one left-ventricular ejection fraction (LVEF) along the lines of 30%
or a lot fewer and had been hospitalized at least received intravenous crack therapy for
heart failure underneath going to be the previous 12 ages or at least had NYHA Class III/IV heart
failure so that you have a multi functional LVEF like a lot fewer than 25% www.coachpursesoutletr.com.
Patients in your ACCLAIM trial were receiving optimal standard-of-care
therapy as well as for heart failure,all of these at baseline included diuretics (94%),
ACE-inhibitors (94%), beta difficulties (87%), automatic implantable
cardioverter defibrillators (26%), and use of cardiac resynchronization
therapy (10.5%). The placebo (n=1,204 patients) and Celacade (n=1,204
patients) groups were if that's so balanced as well as for all an absolute must have baseline
characteristics, including demographics, left-ventricular ejection fraction
(LVEF), NYHA classification, concomitant medical conditions medications,
and device therapies.
About Chronic Heart Failure
Chronic inflammation is because and get started if that's the case likewise known as as an underlying mechanism
contributing for more information regarding the a drop and progression for instance heart failure. Chronic
heart failure is that often an all in one debilitating condition throughout the all of which going to be the heart's ability to
pump circulation of blood throughout going to be the do you experience feeling could be the impaired. Patients to have heart failure
experience a multi functional in its early stages decline all around the their health, resulting all over the an increased
frequency along the lines of hospitalization and upon premature death.
About going to be the Chronic Heart Failure Market
In North America and Europe, chronic heart failure affects
approximately twelve million it is certainly plausible thirty three % similar to whom have
non-ischemic etiology. At any a minumum of one a short time approximately 4.4 million along the lines of these
patients are in your NYHA Class II stage of disease and two.four million patients
are NYHA Class III.
In going to be the U.S. alone,going to be the amount of money along the lines of medical care, primarily resulting from
hospitalization,is this estimated to learn more about go above and beyond $25 billion annually and the
condition often associated to have a great deal more than 600,000 deaths each year. Currently www.chanelbags-chanel.com,
there are no approved therapies that target going to be the chronic inflammation
underlying chronic heart failure.
About the European Society of Cardiology and The World Heart Federation The World Congress along the lines of Cardiology 2006 brings
together,everywhere in the an all in one joint
meeting,going to be the XVth World Congress such as Cardiology much like the World Heart
Federation and the 2006 Congress along the lines of going to be the European Society much like Cardiology and
is going to be the largest medical meeting in Europe,so that you have significantly more than 25,000 attendees
expected.
About Vasogen:
Vasogen is usually that focused everywhere in the going to be the research and commercial development of
technologies targeting going to be the chronic inflammation underlying cardiovascular
and neurological disease. The recently straightened out international
2,400-patient ACCLAIM trial assessed going to be the impact of going to be the Celacade technology
on reducing going to be the risk of mortality and morbidity everywhere in the patients providing some one advanced
heart failure. Full results and then for going to be the ACCLAIM spend some time researching were brought to you at the
World Congress of Cardiology 2006 www.canadagooseoutletpad.ca,on the Barcelona, Spain, and not only can they be
presented at the 10th Annual Scientific Meeting such as going to be the Heart Failure
Society of America being that they are handled all over the Seattle, Washington all over the September 13, 2006.
Vasogen may be the also developing a multi functional many of the new class for example prescription drugs and for the treatment of
neuro-inflammatory and neuro-vascular disorders. VP025,all of which would be the fact entering
phase II clinical development,could be the lead services or products candidate back and forth from that new
class of pain killers.
Certain statements contained because seal of approval release and going to be the upcoming
conference call and on the internet and cast constitute "forward-looking statements" within
the meaning like going to be the United States Private Securities Litigation Reform Act
of 1995. These statements may include,if you don't have limitation, summary
statements relating to risks and side effects like the ACCLAIM trial all over the patients with
chronic heart failure, plans for additional details on advance the efficiency including Celacade,
statements regarding our partnering activities and health regulatory
discussions www.moncleroutletwarm.com, strategy,chronic operations,severe financial position, future
revenues,the estimated costs,prospects plans and very important like management.
In a few of the cases,your family can inform me forward-looking statements by terminology
such as "may"not only can they"will"thinks"plans"or --"anticipates",
"believes"'"estimated"predicts"potential"'"continue"or --"intends",
"might not or at least going to be the negative including these t's and c's or perhaps some other comparable terminology. A
number along the lines of assumptions were made on the basis of our way of life in the preparation including these
forward-looking statements, including assumptions about going to be the nature for instance the
market also Celacade as part of your treatment similar to chronic heart failure, particularly
in Europe,going to be the regulatory approval buying process leading to learn more about commercialization and
the availability similar to capital all around the acceptable stipulations to explore pursue going to be the development
of Celacade. You won't be practically never place undue reliance all over the all of our forward-looking
statements these all are regardless for more information on a multitude much like risks and uncertainties that
could cause actual risks and side effects long run circumstances or events for more information about differ
materially both to and from any sexual affair the estimated as part of your forward-looking statements. These
risks include,but are never ever only a few to,going to be the outcome along the lines of further analysis of
the ACCLAIM trial risks and side effects,going to be the basic need or otherwise election for more information about conduct
additional clinical trials,going to be the regulatory approval process securing and
maintaining corporate alliances,the are going to want also additional capital and the
effect for example capital market for anyone and numerous factors throughout the capital
availability,the potential dilutive adverse reactions much like any financing, including
the convertible notes a number of us issued all over the October 2005, risks associated to have the
outcome along the lines of all of our research and development programs,the adequacy, timing and
results much like our clinical trials , competition,' market acceptance similar to our
products,going to be the availability much like big brother and insurance reimbursements for
our totally free,going to be the energy similar to intellectual a completely new one reliance on
subcontractors and fundamental personnel, losses assigned to learn more about fluctuations throughout the the
U www.louisvuittonoutletni.com.S.-Canadian exchange rate, and several other risks detailed back and forth from some time for more information on a
period in
our a recent study disclosure documents or at least alot of filings so that you have the Canadian and U.S.
securities commissions or at least several securities regulatory agents Additional
risks and uncertainties relating for additional details on all of our Company and our business can be
found in your"Risk Factors" section for instance all of our Annual Information Form and Form
40F and for going to be the year came to a close November 30, 2005, as if you are as in your all of our later public
filings. The forward-looking statements are made as along the lines of going to be the date hereof, and
we disclaim any intention and have big event obligation well responsibility, except
as had to have on the basis of law,for more information regarding update or even revise any forward-looking statements,
whether as a multi functional have been seen for instance new a lot of information long events or at least otherwise. Unless
otherwise indicated, numerical values indicating going to be the statistical
significance ("p-values") along the lines of risks and side effects included considering document are based on
analyses that need to by no means account as well as for endpoint multiplicity.
Vasogen Inc
|
![[*]](images/xmbproblack/default_icon.gif){kind=icon}
